Wyo. Code R. 052-0001-6
Medicine, Board of
Chapter 6: Miscellaneous
Effective Date: 03/07/1997 to 01/29/2003
Rule Type: Superceded Rules & Regulations
Reference Number: 052.0001.6.03071997
(a) At each regularly scheduled meeting, the board shall review reports of malpractice claims against Wyoming licensed physicians reported since the last board meeting.
(b) Based on this review, the board shall determine if further review and/or investigation is necessary under the terms and provisions of the act. If further review and/or investigation is deemed necessary, the matter shall be handled as a board initiated complaint pursuant to chapters 4 and 5 of these rules.
(c) The executive secretary shall compile all reports of malpractice claims from licensees, insurance carriers, attorneys, courts, health care entities, data banks and other reliable sources and maintain statistics for each licensee as to the number, frequency, nature and disposition of such claims.
(a) Final disciplinary orders entered in other jurisdictions against Wyoming licensed physicians shall be handled as follows:
(i) Those with current Wyoming licenses who are practicing in Wyoming may be subject to a board initiated complaint and investigation pursuant to chapters 4 and 5 of these rules.
(ii) Those with current licenses but practicing out of state shall be served with a consent agreement requiring the physician to notify the board in writing at least thirty (30) days prior to returning to the state to practice. A physician's or physician assistant's failure or refusal to sign such agreement may initiate disciplinary proceedings against his/her license.
All final board orders subject to public disclosure pursuant to W.S. 33-26-408(c) shall be sent to any medical facilities where the licensee has privileges, to the appropriate state medical society and to any local county medical society to which the licensee might belong, to a wire service, to the Federation of State Medical Boards, to the National Practitioner Data Bank when applicable, to the Wyoming Board of Pharmacy and to the Federal Drug Enforcement Agency.